Company Overview of SyStemix, Inc.
SyStemix, Inc. was acquired by Novartis AG. In February 1997, SyStemix, Inc. completed a merger with Novartis Biotech Holding Corp., an indirect wholly owned subsidiary of Novartis, Inc., pursuant to which SyStemix became an indirect wholly owned subsidiary of Novartis. Previously, SyStemix, Inc. was engaged in the development of cellular and cell-based gene therapies for cancer, AIDS, and genetic diseases based on the use of isolated, expanded, and gene-modified hematopoietic stem cells.
3155 Porter Drive
Palo Alto, CA 94304
Key Executives for SyStemix, Inc.
SyStemix, Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact SyStemix, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.